Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM.

Cancer Discov. 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14.

PMID:
29903880
2.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

PMID:
29247021
3.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).

Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ.

Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22.

4.

The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning.

Marusina K, Welsch DJ, Rose L, Brock D, Bahr N.

Drug Discov Today Ther Strateg. 2011 Winter;8(3-4):77-83.

5.

Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).

Carron CP, Trujillo JI, Olson KL, Huang W, Hamper BC, Dice T, Neal BE, Pelc MJ, Day JE, Rohrer DC, Kiefer JR, Moon JB, Schweitzer BA, Blake TD, Turner SR, Woerndle R, Case BL, Bono CP, Dilworth VM, Funckes-Shippy CL, Hood BL, Jerome GM, Kornmeier CM, Radabaugh MR, Williams ML, Davies MS, Wegner CD, Welsch DJ, Abraham WM, Warren CJ, Dowty ME, Hua F, Zutshi A, Yang JZ, Thorarensen A.

ACS Med Chem Lett. 2010 Feb 2;1(2):59-63. doi: 10.1021/ml900025z. eCollection 2010 May 13.

6.

Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo.

Nemirovskiy OV, Dufield DR, Sunyer T, Aggarwal P, Welsch DJ, Mathews WR.

Anal Biochem. 2007 Feb 1;361(1):93-101. Epub 2006 Nov 15. Erratum in: Anal Biochem. 2007 Nov 15;370(2):258.

PMID:
17187753
7.

Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis.

Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ.

Osteoarthritis Cartilage. 2006 Nov;14(11):1189-95. Epub 2006 Jun 6.

8.

The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.

Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, Lala DS, Welsch DJ, Hu X.

Mol Endocrinol. 2005 Jun;19(6):1460-73. Epub 2005 Mar 10.

PMID:
15761029
9.

Metalloproteases and inhibitors in arthritic diseases.

Martel-Pelletier J, Welsch DJ, Pelletier JP.

Best Pract Res Clin Rheumatol. 2001 Dec;15(5):805-29. Review.

PMID:
11812023
10.

Lipid remodeling in mouse liver and plasma resulting from delta6 fatty acid desaturase inhibition.

Duffin KL, Obukowicz MG, Salsgiver WJ, Welsch DJ, Shieh C, Raz A, Needleman P.

Lipids. 2001 Nov;36(11):1203-8.

PMID:
11795852
11.

Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.

Freskos JN, Mischke BV, DeCrescenzo GA, Heintz R, Getman DP, Howard SC, Kishore NN, McDonald JJ, Munie GE, Rangwala S, Swearingen CA, Voliva C, Welsch DJ.

Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.

PMID:
10230616
12.

Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice.

Obukowicz MG, Welsch DJ, Salsgiver WJ, Martin-Berger CL, Chinn KS, Duffin KL, Raz A, Needleman P.

J Pharmacol Exp Ther. 1998 Oct;287(1):157-66.

13.

Modulation of adjuvant-induced arthritis by dietary arachidonic acid in essential fatty acid-deficient rats.

Chinn KS, Welsch DJ, Salsgiver WJ, Mehta A, Raz A, Obukowicz MG.

Lipids. 1997 Sep;32(9):979-88.

PMID:
9307941
14.

Molecular cloning and expression of human leukotriene C4 synthase.

Welsch DJ, Creely DP, Mathis KJ, Hauser SD, Isakson PC.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:167-9. No abstract available.

PMID:
7732826
15.

Molecular cloning and expression of human leukotriene-C4 synthase.

Welsch DJ, Creely DP, Hauser SD, Mathis KJ, Krivi GG, Isakson PC.

Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9745-9.

16.

Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli.

Gustafson ME, Junger KD, Wun TC, Foy BA, Diaz-Collier JA, Welsch DJ, Obukowicz MG, Bishop BF, Bild GS, Leimgruber RM, et al.

Protein Expr Purif. 1994 Jun;5(3):233-41.

PMID:
7950366
18.

Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells.

Wun TC, Kretzmer KK, Palmier MO, Day KC, Huang MD, Welsch DJ, Lewis C, Wolfe RA, Zobel JF, Lange GW, et al.

Thromb Haemost. 1992 Jul 6;68(1):54-9.

PMID:
1325078
19.
20.

Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").

Watzke HH, Lechner K, Roberts HR, Reddy SV, Welsch DJ, Friedman P, Mahr G, Jagadeeswaran P, Monroe DM, High KA.

J Biol Chem. 1990 Jul 15;265(20):11982-9.

21.

Partial purification and characterization of bovine liver aspartyl beta-hydroxylase.

Gronke RS, Welsch DJ, VanDusen WJ, Garsky VM, Sardana MK, Stern AM, Friedman PA.

J Biol Chem. 1990 May 25;265(15):8558-65.

24.
25.

Chemical modification of prothrombin fragment 1: documentation of sequential, two-stage loss of protein function.

Welsch DJ, Pletcher CH, Nelsestuen GL.

Biochemistry. 1988 Jun 28;27(13):4933-8.

PMID:
3167021

Supplemental Content

Loading ...
Support Center